One Capital Management LLC Has $1.75 Million Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

One Capital Management LLC raised its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 61.1% during the fourth quarter, HoldingsChannel reports. The firm owned 74,973 shares of the biopharmaceutical company’s stock after acquiring an additional 28,433 shares during the quarter. One Capital Management LLC’s holdings in Catalyst Pharmaceuticals were worth $1,750,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of CPRX. Royal Bank of Canada boosted its holdings in shares of Catalyst Pharmaceuticals by 39.1% in the 1st quarter. Royal Bank of Canada now owns 213,469 shares of the biopharmaceutical company’s stock valued at $5,177,000 after purchasing an additional 60,040 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Catalyst Pharmaceuticals by 5.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,052 shares of the biopharmaceutical company’s stock valued at $1,749,000 after acquiring an additional 3,800 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Catalyst Pharmaceuticals by 11.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after acquiring an additional 333,100 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 99.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 526,297 shares of the biopharmaceutical company’s stock valued at $12,763,000 after acquiring an additional 262,392 shares in the last quarter. Finally, Intech Investment Management LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 6.5% during the 1st quarter. Intech Investment Management LLC now owns 70,087 shares of the biopharmaceutical company’s stock valued at $1,700,000 after acquiring an additional 4,261 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Up 0.0%

Shares of NASDAQ:CPRX opened at $31.28 on Thursday. The firm has a market cap of $3.83 billion, a P/E ratio of 17.98, a P/E/G ratio of 0.95 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a 12-month low of $19.05 and a 12-month high of $32.56. The business has a fifty day simple moving average of $28.13 and a 200 day simple moving average of $25.23.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on CPRX. Citigroup downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $35.00 to $31.50 in a report on Friday, May 8th. HC Wainwright downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $35.00 to $31.50 in a report on Thursday, May 28th. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Oppenheimer downgraded Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Finally, Robert W. Baird downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).